Modeling how the immune system reacts to transplanted organs using advanced technology.
Official title: Vascularized liver-heart on-a-chip modeling antibody-mediated rejection and tolerance of allografts
Funded at Terasaki Institute for Biomedical Innovation · NIH-10860820 · Data updated 2026-11-12
This study is looking at how the immune system reacts to transplanted organs, like the liver and heart, to find out which antibodies might cause rejection, with the hope of helping transplant patients have better outcomes and less need for long-term medication.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Terasaki Institute for Biomedical Innovation NIH-funded |
| Lab location | 1 site (Woodland Hills, UNITED STATES) |
| Project start | August 14, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $611,129 |
| NIH project number | 1R01AI183529-01 |
| Project ID | NIH-10860820 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have received or are considering organ transplants, particularly of the liver or heart.
✕Less likely to help
Patients who are not candidates for organ transplantation or those with conditions unrelated to organ rejection may not benefit from this research.
What this research studies
This research focuses on understanding how the immune system responds to transplanted organs, particularly in the context of antibody-mediated rejection. By developing a multi-organ-on-a-chip platform, the study aims to simulate the interactions between the liver and heart to identify specific antibodies that may lead to rejection of transplanted organs. This innovative approach allows researchers to study these complex interactions in a controlled environment, potentially leading to better diagnostic tools and treatment strategies for transplant recipients. Patients may benefit from insights gained through this research, which could improve transplant outcomes and reduce the need for lifelong immunosuppression.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing organ rejection in transplant patients.
How similar studies have gone: While organ-on-a-chip technologies are gaining traction, this specific approach to studying antibody-mediated rejection is relatively novel and has not been extensively tested.
Where this research is happening
-
Terasaki Institute for Biomedical Innovation
Woodland Hills, United States Active
Researchers
- Principal investigator: Jucaud, Vadim — Terasaki Institute for Biomedical Innovation
- Study coordinator: Jucaud, Vadim
Related research
Other NIH-funded projects on the same topics.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
Immunological mechanisms behind treatment-resistant kidney transplant rejection
This grant explores why certain kidney transplant rejections don’t respond to standard treatments and what immune cells in the graft are driving that resistance.
-
Targeting graft T cells to reduce transplant rejection
A patient-facing study exploring how immune cells within transplanted organs drive rejection and how we might reduce trouble for people who need organ transplants.
-
Engineered kidney 'chip' to study antibody-driven rejection and how the body adapts
A kidney-rejection research grant is developing a miniaturized, human cell–based chip to model how antibodies cause rejection and how kidneys may adapt.
-
Social media, mood, and teens: how the menstrual cycle affects rejection feelings and online experiences
Teenagers using social media may feel stronger negative reactions to online feedback, especially around certain times in their menstrual cycle, which could relate to mood and depression.
-
Understanding how BK virus links infection to kidney transplant rejection
This project looks at how BK polyomavirus reactivation affects kidney transplant patients and aims to use pre-transplant T cell information to tailor immunosuppression and monitoring.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.